A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2029-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS). The study seeks to determine whether oral taurine can reduce the number and volume of new or enlarging MRI lesions, decrease relapse rates, and slow disability progression as measured by the Expanded Disability Status Scale (EDSS). It will also explore the effects of taurine on gut microbiota composition, serum neurodegeneration biomarkers (GFAP and NfL), and cognitive function assessed by MMSE and MoCA. Approximately 80 eligible participants will be enrolled and randomly assigned to either continue standard DMT therapy or receive taurine supplementation in addition to DMTs. The treatment duration will be 24 months, with follow-up visits every 3 months for clinical assessment, blood and stool sample collection, and MRI scans every 6 months. This study aims to provide new clinical evidence supporting taurine as a safe and potentially beneficial adjunctive therapy for multiple sclerosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

NCT02903537

Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Chronic Progressive

UNKNOWN PHASE1

A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

NCT07020715

Multiple Sclerosis

NOT_YET_RECRUITING PHASE2

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

NCT01051817

Relapsing-remitting Multiple Sclerosis RRMS

COMPLETED PHASE2

Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation

NCT00342381

Multiple Sclerosis Fatigue

COMPLETED PHASE2

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05134441

Multiple Sclerosis

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis (MS) Relapsing Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taurine + DMTs

Experimental group

Group Type EXPERIMENTAL

DMTs + taurine

Intervention Type DRUG

DMTs + Taurine

DMTs

control

Group Type PLACEBO_COMPARATOR

DMTs

Intervention Type DRUG

DMTs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DMTs + taurine

DMTs + Taurine

Intervention Type DRUG

DMTs

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.Age and Gender: Male or female participants aged 18 to 65 years.
* 2.Diagnosis: Patients diagnosed with multiple sclerosis (MS) according to the 2017 revised McDonald criteria.
* 3.Treatment Background: Patients receiving stable disease-modifying therapy (DMT) prior to enrollment.
* 4\. EDSS score between 1.0 and 5.5 at screening.
* 5\. Compliance: Ability and willingness to comply with all study procedures, follow-up visits, and study medication requirements.
* 6.Informed Consent: Participants must provide written informed consent before any study-specific procedures are performed.
* 7 Female participants must be non-pregnant and non-lactating, or, if of childbearing potential, must agree to use effective contraception during the study

Exclusion Criteria

* 1\. Patients with known hypersensitivity to taurine or any of its components
* 2\. Women who are pregnant or breastfeeding
* 3\. Patients currently participating in other clinical trials
* 4\. Patients who refuse to participate in the relevant clinical study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No